Format

Send to

Choose Destination
Oncotarget. 2017 May 23;8(21):34310-34320. doi: 10.18632/oncotarget.16110.

Robust in-silico identification of cancer cell lines based on next generation sequencing.

Author information

1
Knowledge Management in Bioinformatics, Institute for Computer Science, Humboldt-Universität zu Berlin, Berlin, Germany.
2
Charité Universitätsmedizin Berlin, Institute of Pathology, Berlin, Germany.
3
DKTK, German Consortium for Translational Cancer Research, Partner Site, Berlin, Germany.

Abstract

Cancer cell lines (CCL) are important tools for cancer researchers world-wide. However, handling of cancer cell lines is error-prone, and critical errors such as misidentification and cross-contamination occur more often than acceptable. Based on the fact that CCL today very often are sequenced (partly or entirely) anyway as part of the studies performed, we developed Uniquorn, a computational method that reliably identifies CCL samples based on variant profiles derived from whole exome or whole genome sequencing. Notably, Uniquorn does neither require a particular sequencing technology nor downstream analysis pipeline but works robustly across different NGS platforms and analysis steps. We evaluated Uniquorn by comparing more than 1900 CCL profiles from three large CCL libraries, embracing 1585 duplicates, against each other. In this setting, our method achieves a sensitivity of 97% and specificity of 99%. Errors are strongly associated to low quality mutation profiles. The R-package Uniquorn is freely available as Bioconductor-package.

KEYWORDS:

DNA-sequencing; cancer cell lines; cell line-identification; data-heterogeneity and incompleteness; next-generation sequencing

PMID:
28415721
PMCID:
PMC5470969
DOI:
10.18632/oncotarget.16110
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center